Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)

Status:
Completed

Trial end date:
2008-10-01

Target enrollment:

Participant gender:

The purpose of this study is to evaluate the safety of long-term treatment with HZT-501.

Phase 3

Horizon Pharma Ireland, Ltd., Dublin Ireland

Famotidine
Ibuprofen